Latest news

Quote

Anonymous

Guest
1-Star Stocks Poised to Plunge: Cadence Pharmaceuticals?

Cadence has gapped down on earnings the last three quarters and I don't see that as likely to change on August 2. Ofirmev revenues have been increasing moderately behind a furious marketing drive but are still a long way from matching SGA expenses and quarterly burn. With the share price up 50% from recent lows as the summer tide lifts the biopharma sector, look to Cadence to be at the forefront of the wave back downward.


Let's see if this guy is right or not. I hope not.
 






Anonymous said:
1-Star Stocks Poised to Plunge: Cadence Pharmaceuticals?

Cadence has gapped down on earnings the last three quarters and I don't see that as likely to change on August 2. Ofirmev revenues have been increasing moderately behind a furious marketing drive but are still a long way from matching SGA expenses and quarterly burn. With the share price up 50% from recent lows as the summer tide lifts the biopharma sector, look to Cadence to be at the forefront of the wave back downward.


Let's see if this guy is right or not. I hope not.
Click to expand...

This company sucks, don't get me wrong, but you're quoting Mötley Fool? Is MTV your source for the latest from Syria?
 












Hey, for those of us who work here and follow sales trends, its obvious to everyone who knows the numbers that we will be well ahead of Q2 forecast. Expenses will be down also. Stock price is going to be above $5.00 after August report. You can take that to the bank.
 












Anonymous said:
Hey, for those of us who work here and follow sales trends, its obvious to everyone who knows the numbers that we will be well ahead of Q2 forecast. Expenses will be down also. Stock price is going to be above $5.00 after August report. You can take that to the bank.[/QUOTE

Wow 5 bucks tío nada UFO used to be 10
Click to expand...
 






Top Bottom
Back
Quote